Clinical Trials Transparency and Reporting

St George’s University of London (SGUL) and St George’s University Hospitals NHS Foundation Trust (SGHFT) fully support the moves to ensure greater transparency in clinical trials and support the use of data sharing providing it preserves and maintains patient confidentiality. These principles are important for ethical, moral, accountability, research integrity and waste reduction perspectives, to foster a relationship of confidence with patients and members of the public and to ensure compliance with our legal obligations.

Our approach will take into consideration the WHO Joint Statement on public disclosure of results from clinical trials and is consistent with our responsibilities under the EU Clinical Trailed Directive and the Health Research Authority’s UK Policy Framework for Health and Social Care Research.

Clinical trial/research registration

All applicable clinical trials and studies of an interventional nature sponsored by either SGUL/SGHFT will be required to prospectively register on a WHO recognised clinical study/trials register prior to the start of the trial/ before the 1st patient/participant is recruited. For clinical (drug) trials (i.e. those requiring MHRA approval), using the EU’s Clinical Trials Register (EUCTR) is mandatory. and or the International Standard Randomised Controlled Trial Number Register (ISRCTN) are other optional registries.

Registry information will be kept up to date on a regularly basis in line with any changes to recruitment data and key outcomes. Any approved changes to the protocol need to be updated on the registry as early as possible by the Chief Investigator.

Responsibility for timely trial Registration resides with the Chief Investigator of the study however accountability will reside with SGUL/SGHFT as the sponsoring organisation. The Joint Research and Enterprise Service (JRES) will monitor this in line with the oversight of trial set up.

SGUL/SGHFT recognise the importance for our local patient and public population to be aware of the clinical trials and research occurring on either of our sites. We have created a search function on our public facing research website, linked to our R&D database, primarily for the local public to search for trials conducted on site/by us. We will be expanding this by creating a function to provide links to published results of our sponsored projects. This is an additional, local initiative to promote transparency of our research portfolio on site.

Publication of trial findings

SGUL/SGH acknowledges that a fundamental principle of conducting clinical research is that findings must be published/disseminated regardless of whether they are seen to be positive or negative. Publication in a Peer-Reviewed journal or platform is required for all relevant research projects. We will aim to ensure appropriate publication of research findings within an indicative timeframe of 24 months from Primary Study Completion. Where any fee is payable to ensure Open Access, this may be paid in accordance with our Open Access Policy.

It is SGUL/SGHFT policy to pursue appropriate funding for its interventional research and clinical trials from external sources i.e. medical research councils, charities and government funding sources such as the NIHR. Dissemination policy of the funder will be adhered to.

Where appropriate, trial findings will be disseminated to participants and others involved in the research once results have been published and if they have consented to be kept informed (in line with the original ethics submission and information sheet).

Responsibility for timely publication and dissemination of findings within a Peer-Reviewed Open Access journals and or to patients/public resides with the Chief (Principal) Investigator. Accountability resides with SGUL/SGHFT as sponsoring organisation. The JRES will monitor this in line with the oversight of trial closure.

Reporting trial findings on a Clinical Trials register

It is a legal obligation that all interventional clinical trials (i.e. those requiring MHRA approval) sponsored by SGUL or SGHFT are updated on the EUCTR (via the EudraCT system) within 12 months of the trial completion date (or within 6 months for paediatric trials).

The EudraCT system can be accessed here. A user guide for the EudraCT system can be accessed via the website.

Responsibility for timely trial registry completion resides with the Chief Investigator (CI) of the study however accountability will reside with SGUL/SGHFT as the sponsoring organisation.

Once a trial completion date has been reached, the JRES (in liaison with the Chief Investigator) will complete the entry for the clinical trial on the EudraCT system as far as possible with the information held by JRES. The Chief Investigator will then complete the remainder of the information required to report on the EudraCT system and submit the report on EudraCT promptly, and at the latest by 12 months after the trial completion date (or within 6 months for paediatric trials).

The JRES will monitor monthly outstanding clinical trials that are due to report and will remind the Chief Investigator if a trial is outstanding, and in the event of non-response will escalate the issue to the Deputy Principal (Research & Enterprise) for SGUL sponsored trials and the Associate Medical Director (Research) for SGHFT sponsored trials.

To ensure effective oversight, the JRES will provide a report each quarter to the Research Governance Committee on the number of clinical trials which are due to report on the EUCTR which have not yet reported.

Sharing research data

Research data are an important output from Clinical Trials and projects and it is expected that there is the ability for appropriate re-use of data. This is important because re-use of data increases the impact resulting from the initial financial, research infrastructure, and research participants’ investments needed to collect data. Appropriately anonymised datasets from our sponsored research will be made available for further analysis wherever possible.